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Abstract
Recent advances in cell reprogramming have permitted the development of different stem cell
lines and specific differentiated cell types using distinct technologies. Cell reprogramming is
largely mediated by DNA and RNA. In this review, we explore the RNA mediated cell
reprogramming to induce specific target cell generation including stem cells, brain cells and
cardiac cells. The ability of RNA populations to produce direct cell to cell phenotypic conversion
is called Transcriptome Induced Phenotype Remodeling (TIPeR). The theory and utility of RNA
use for cellular reprogramming is explored in this review.
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Cellular reprogramming
The historical view of cellular development states that cells require specific cues to
proliferate and differentiate, and then require guidance to form tissues and further organize
into complete organs. This is a unidirectional process culminating in cells that are terminally
differentiated in a manner based on their lineage. According to this long-standing theory,
this is caused by an irreversible loss in expression of functional genes within that particular
cell as well as the activation of selective genes.
All information in cells and tissue is essentially derived from the master blueprint of DNA.
This suggests that, transferring the DNA from one cell to another should transfer all
information about the donor to the recipient. To test this theory, many laboratories have used
the technique of somatic nuclear transfer (SNT), pioneered by Xenopus somatic nuclei
transplants to make tadpole clones [1]. Many years later, this technically difficult procedure
was successful in mammalian cells, most famously producing the cloned sheep, Dolly [2, 3].
This and other such successes provided hope that these techniques would result in
production of cells that will have regenerative medicinal uses such as the production of
specific organs or cells for therapeutic use in long-term or terminal diseases [4].
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In the early 1960’s, a series of experiments were performed where in mice experienced
whole-body radiation followed by transplantation of bone marrow from normal mice. The
bone marrow cells repopulated the irradiated mice with normal circulating cells. These
experiments yielded the first hints of the existence of undifferentiated but proliferative cell
types, which were later defined as stem cells [5]. This was an exciting development because
in addition to a potential for cloning an entire animal, stem cells offered immediate potential
for clinical applications such as cell therapy without the need for a complicated processes
such as SNT. Further, the pluripotency of these cells implied greater cell-type availability
for various therapeutic uses. In addition to embryonic stem cells, the discovery of the
presence of adult stem cells has also generated great interest in anticipation of clinical
applications including transplantation [6].
Most recently based on earlier genomic research in stem cells, a subset of transcription
factors was used to generate induced pluripotent cells (iPS) [7]. The selection of highly
expressed transcription factors in ES cell lines and frequently upregulated genes were
utilized to induce stem cells. This approach has rapidly stimulated research in
reprogramming somatic cells into pluripotent stem cells. Subsequent research has focused
on combining different transcription factors for more efficient stem cell generation and
different transfection strategies [8–12]. These initial iPS studies utilized promoter driven
cDNA constructs as the transferred agents to induce phenotypic change upon expression in
fibroblasts. This DNA transcription factor-mediated methodology has also been used to
transdifferentiate (directly convert without going through the stem cell intermediate)
fibroblasts to iCardiomyocyte (induced Cardiomyocyte-like cell) and also pancreatic
exocrine cells into β-cell-like cells in vivo [13, 14].
Simultaneously a distinct but novel approach was developed. Here a host cells’s phenotype
was directly converted by transplanted mRNA from a donor cell. The host cell then
undergoes a phenotypic conversion and stably expresses the donor cell phenotype [15]. This
method has been used to convert post-mitotic neurons have been converted to tAstrocytes
while fibroblasts as well as astrocytes have been converted into tCardiomyocytes [16].
There are three fundamental differences between these approaches (Figure 1). (i) In nuclear
transfer, the innate programming capability of the totipotent cell is used to drive
transformation. (ii) In iPS cells, transcription factors are used to drive quiescent DNA
transcription. (iii) In TIPeR, the RNA complement present in a functional cell is introduced
to transform the cell state. In this review, we will focus on recent research in inducible stem
cell generation and direct cell differentiation by phenotype remodeling. A detailed
discussion of the methodological differences between these techniques is beyond the scope
of this review, and we will instead discuss the process of cell differentiation through
reprogramming and remodeling, comparing the concepts and the hopes for such
technologies[17].
Nuclear transfer
Despite its low efficiency and unavoidable ethical issues, nuclear transfer is the easiest
available method to produce totipotent cells that will most closely mimic the natural cell
linage development process. Totipotency is only present and maintained through very early
stages of development following fertilization; cells generated from ES lines are by definition
pluripotent because they are derived from cells in later stages of development. This method
has been used recently to generate pluripotent embryonic stem cell lines from mammals
including mice and monkeys [18, 19]. So far, a cell line from human origin has not yet been
generated using this method, the prospect of which faces ethical roadblocks [20]. Currently
available totipotent cells obtained from animal models, combined with genomics and
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proteomics analytical tools, can be used to characterize the gene set that is necessary for
self-renewability and the maintenance of pluripotency, including the transcription factors
required at specific developmental stages.
DNA-mediated introduction of transcription factors to induce phenotypic
conversion
Based on genomics level transcriptome analysis of stem cell gene activation, inducible stem
cells have been produced using four transcription factors. The method has generated new
possibilities for understanding how to reprogram somatic cells to dedifferentiate. This is
akin to the development of a continuous cell line upon induction of cancer by an oncogene.
Using selected transcription factors, maintained at high abundance in pluripotent stem cells,
terminally differentiated somatic fibroblasts were induced to become pluripotent stem cells
through reprogramming. These cells have a phenotypic resemblance to embryonic stem cells
and are capable of differentiation into neurons and cardiomyocytes [21, 22]. Hence, somatic
cells are capable of dedifferentiation into self-renewable stem cells.
DNA mediated iPS technology provides an alternative to nuclear transfer that is easily and
immediately applicable to the pharmaceutical industry for efficient drug design and for
testing efficacy within a uniform population of cells sharing the same status through tight
control of cell lineage. However, some aspects of the generation of these cells should still be
taken into consideration when contemplating their use. Retroviral insertion of transcription
factors into the genome occurs randomly, allowing no control over the insertion site and
potential for the development of mutagenesis. Digital quantification of mutations has
revealed that multiple mutations are present in many different existing iPS cell lines that are
currently in use [23]. In order to address this issue, alternative methods such as transduction
with adenovirus vectors or transfection using plasmid vectors has been used to generate iPS
cells but at a significant loss of efficiency compared to retroviral transduction[24–26]. This
suggests that the overexpression of transcription factors may be necessary to gain highly
efficient iPS cell generation. A cautionary aspect of viral mediated generation of iPS cells is
that viral vector transduction without reprogramming transcription factor genes also
produced iPS cells, which suggests that vector-induced insertional mutation caused somatic
cell reprogramming [27].
For use in regenerative medicine, it is critical that cells introduced for treatment are stably
differentiated and will not develop into undesired cell types [28, 29]. Many of the commonly
employed iPS factors are enriched in pluripotent blastoma cells, for example, the well-
known oncogenes Oct4 and Myc. This enrichment raises concerns that the over-expression
of these factors may not result in generation of a long-term stable phenotype [30, 31]. An
alternate approach used by the other groups, entails the generation of iPS cells by omitting
oncogenes and using DNA-mediated introduction of other transcription factors [9–11].
Induction of epiblast stem cells using the DNA-driven iPS method with modified culture
conditions [32, 33]. This finding demonstrates that a subpopulation of inhomogeneous cells
may be generated using current methods for producing iPS cells, and may potentially
present a future risk. The extent of this population has not yet been determined. The ability
to use autologous somatic cells for induction of iPS and subsequent cell types from a patient,
is expected to reduce issues related to immunohistocompatibility[34]. Unexpectedly,
however, in a recent report highly expressed levels of Zg16 and Hormad1 were observed in
transplanted differentiated cells, resulting in transplant immunorejection [35]. Therefore,
prior to clinical application, further research and verification of long-term stability of
differentiated cells from iPS intermediates should be undertaken.
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Considerations with regard to cell phenotype
Recent progress in genomics and proteomics research reveals significant variation in protein
and RNA abundances between individual cells that share a common phenotype [36].
Phenotypic marking is essential to isolate lineages after a differentiation protocol in order to
raise target cells from stem cells. However, stem cell phenotypic identification may not be
as straightforward as identifying cell types from a fixed sample. Cellular phenotype results
from the orchestration of genomic and proteomic activities and is influenced by
biochemistry and physiology. It is important to view these biological activities as dynamic
regulators that act to maintain the cell’s state within given phenyotypic boundaries mRNA
and protein quantities are likely to be present at set ratios in fully differentiated cells, but are
likely to vary widely within the stem cell in response to signals from environmental or
genetic cues. Therefore, the general upstream (unregulated transcription factor expression
after transfection) genetic modification of cell fate regulators may increase the risk that a
cell is directed to an unexpected lineage.
Ideally, identifying a precise gene network interaction map in conjunction with an accurate
and precise method for inserting known amounts of transcription factors or other modulators
of transcription, would make transcription based reprogramming of somatic cells to stem
cells a good choice for clinical and therapeutic applications. Even though there are many
methods to introduce transcription factor DNAs into to a cell, elimination of nonspecific
gene activation following differentiation is difficult. DNA-mediated introduction of
transcription factors requires a promoter, exogenous or endogenous, to drive expression of
the transgene. Exogenous promoters are difficult to control even with the presumably
regulatable promoters, usually resulting in aberrant over-expression of the transgene. This
problem becomes more serious in therapeutic applications.
mRNA induced phenotype conversion
Phenotype generation through direct cell transdifferentiation is preferable to having to go
through the intermediate pluripotent stem cell stage. Recent studies designed to assess the
importance of expression profiles (relative RNA abundances) in cells, demonstrated that it is
possible to convert cell phenotypes through transfer of mRNA populations. This method,
called Transcriptome Induced Phenotype Remodeling (TIPeR) is used to directly transfer
cell phenotypes without using vectors and eliminates the need to first de-differentiate
followed by re-differentiation. This was first exampled using cells from the central nervous
system. Neurons and astrocytes are both derived from the same ectodermal tissue, but gain
different function, physiology, and anatomy during development, and accordingly express
different proteins. Using TIPeR, neurons were converted to astrocyte-like cells as
determined by quantitation of multiple phenotypic measures. These results demonstrated the
viability of the TIPeR approach in eliciting somatic cell to cell conversion. This approach
has several advantages over DNA-mediated phenotypic conversations. In this method, using
specific RNAs avoids activation of non-relevant genes and pathways driven by the difficult
to control promoter-driven over-expression of transcription that may incorrectly activate
networks of gene expression that are inappropriate in a specific desired cell type.
Transcriptome transfer from donor cell to the host cell modifies the level of various mRNAs
within the host cell mRNA population. This modification of the transcriptome is achieved
by either repetition of the TIPeR process or increasing the amount of mRNAs added until a
sufficient level is reached to drive phenotypic conversion to a stable epigenetic landscape
(Figure 2) [36]. A major advantage of using mRNA to drive transformation is that its
expression in the host cell is transient due to the cellular degradation of mRNA. Once the
transfected mRNA has been translated it is degraded by natural cellular processes and will
not generate unwanted long-term effects. In addition to this, the donor cellular mRNAs used
Sul et al. Page 4
Trends Biotechnol. Author manuscript; available in PMC 2013 May 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
in some TIPeR methods also include all forms of the destination cell mRNA population
including various alternatively spliced and edited forms. Therefore differences in post-
transcriptional modifications that may be specific to a given cell type, such as splicing,
should not be limiting by the use of only a single type of mature mRNA (Table 1) [37–40].
TIPeR of selected transcription factor mRNAs has also been used to generate a pluripotent
stem cell. The recent report from the Givol group using mRNA derived from four
transcription factors used to create iPS cells was the first to demonstrate the successful
RNA-mediated generation of iPS clones from fibroblasts [39]. This was followed by similar
reports from Warren et al. and Plews et al. that further confirm the idea of RNA mediated
cellular reprogramming to generate stem cells [38, 41]. The Warren et al. paper used
chemically modified mRNA that presumptively increases the cellular half-life of the
transfected RNAs but it should be noted that this modification is not necessary for the
functioning of the mRNAs or to create phenotypic conversion or to maintain cell viability.
Many studies have demonstrated that the transfection of unmodified mRNAs, and
unmodified small interfering RNAs were functional without apparent drawbacks [15, 16, 39,
42, 43] [44]. Technically, it may be of note that adding a poly-A tail and capping the in vitro
transcribed mRNA may improve the efficiency of translation and stability of mRNA but any
modifications should be examined experimentally to verify the effects of modifications. As
the RNA mediated induction of stem cell is distinct from the DNA-mediated method and
involves two or more RNAs, it should be designated as transcriptome mediated pluripotent
stem cell (tPS).
tPS cells have also been produced by performing TIPeR of fibroblasts using a specific
miRNA [40]. This observation further suggests the importance of the dynamic expression
state of a cell as a dominant determinant of cell phenotype in as much as miRNAs work to
generally suppress expression of either gene transcription or protein-translation. Whereas
mRNA TIPeR generally produces a gain of function (increased protein production) miRNA
TIPeR would produce a loss of function (decrease in protein production). miRNAs act in a
linear manner meaning that an individual miRNA will bind to one target site and exert its
inhibitory function. As there are generally multiple binding sites for any particular miRNA
in several mRNAs of the expressed transcriptome, the miRNA will act to inhibit the
expression of several mRNAs (Figure 3).
The success of TIPeR of both mRNAs and miRNAs in altering the phenotype of cells can be
viewed in context of the Waddington’s original epigenetic landscape theory [45]. However,
TiPeR shows that this epigenetic landscape can be considered more as a barrier to keep the
cell within a phenotypic range of common expression, and can be modified through the
addition of exogenous elements. Thus, a single cell’s specific epigenetic landscape contains
common factors shared across a given cell type (eg neuron, cardiomyocyte) as well as an
individual transcriptome signature with a unique frequency and amplitude. The success of
cell type conversion will be dependent on the strength of exogenous forces to modulate
those variable elements to ease the TiPeR process. mRNA TIPeR would increase the amount
of selected functional mRNAs and proteins altering their cellular ratios in an effort to go
over the epigenetic barriers to transdifferentiation. In conjunction with this action, miRNA
TIPeR can be thought of as through inhibition of mRNA and protein production as lowering
of the epigenetic barrier to transdifferentiation. The result of either process would be the
transdifferentiation of the host cell into the destination cell. It is likely that future TIPeR
mediated transdifferentiation will exploit the use of both gain of function (mRNA) and loss
of function (miRNA) constituents to exert finer control over the transdifferentiation process.
The TIPeR technology is in its infancy hence there are still many unanswered questions
including - how do the mRNAs that produce a particular transdifferentiation event compare
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with the mRNAs that are inhibited by miRNAs that produce the same transdifferentiation?
Also does one need more molecules of a miRNA to elicit a phenotypic change as compared
to mRNAs that would create the same destination phenotype? These are fundamental
questions that bear on how cells develop and the pathways through which they can be
manipulated to produce the desired phenotype. The importance of such questions and the
ease in the use of RNAs for transdifferentiation highlights the advantages of direct RNA use,
as opposed to DNA driven expression (Box 1).
Future directions and conclusions
To achieve high efficiency direct somatic cell phenotype remodeling, there needs to be
extensive understanding of the quantitative aspects of the specified cells phenotypic status.
In general the most important phenotypic marker to consider is the functionality of the cell.
The phenotype of cells after differentiation is a dynamic state resulting in balancing of
functional proteins and RNAs to maintain homeostasis of specific functional phenotype. The
success of RNA and DNA mediated cellular phenotypic conversions demonstrates that
breaking proteomic homeostasis in terminally differentiated cells through the expression of
selected RNAs can produce cellular reprogramming regimens. The efficiency of this
procedure not only depends on the efficiency or introduction of the mediators (e.g.
transcription factors for iPS) but also likely relies on the cells phenotypic status. This status
as dictated by the cellular expression profile can be thought of as the phenotypic or cellular
memory. This cellular memory can be represented as a 3-dimensional space bounded by the
expression profiles of all cells of a particular phenotypic status. For a cell near the shell edge
it may be possible for this cell to be more easily modified by TIPeR into a distinct cell type
then one on the opposite edge of the same phenotypic shell. In addition to the uncertainty of
determining a precise site of insertion, the copy number, and the efficiency of DNA-
mediated insertion of transcription factors, a cell’s initial phenotypic status will play an
important role in the reprogramming process. Transcriptome mediated remodeling utilizes a
transcriptome generated from a donor cell culture or multiple RNAs that have been mixed in
selected ratios. Pooling the transcriptomes from many cells of the same type will limit the
effect of single cell variation, as transfection of a homogeneous transcriptome into acceptor
cells reduces the variability originating from multiple transfections introducing
heterogeneous single cell transcriptomes. The method of transcriptome mediated cell
remodeling utilizes the innate proteomic and biochemical enzyme system of the host cell as
the machinery for remodeling, in contrast to the stereotyped, iterative, reprogramming that is
necessary in transcription factor stimulated iPS development. Although this may delay the
immediate conversion of a cell to another type, the principles underlying the TIPeR process
have a clear benefit in therapeutic applications as it opens up the possibility of on-site, direct
remodeling of target cells in tissue without first isolating the cells. This possible tissue
specific use of TIPeR has another potential benefit as cells undergoing changes in vivo will
be subject to epigenetic and environmental influences from surrounding healthy tissue.
As TIPeR may refer to either whole transcriptome or partial transcriptome transfer into a
host-cell it is important to note the advantages and disadvantages of each. The advantage of
using the whole transcriptome to elicit phenotypic conversion is that the donor RNAs are
present in the ratios and amounts required for the sought after phenotype to function. This is
an unbiased approach to generation of cellular phenotype. Further there may be specific
splice variants, RNA-edited forms of the endogenous RNA or endogenous poly-A tail
lengths, that are required for proper expression and phenotypic conversion that would not be
available from available transcribable cDNA clones. The primary limitation of this approach
is that a source of the whole transcriptome will be necessary for transfer and such sources
(especially for human phenotypic transfers) may be limiting. On the other hand, use of
defined selected RNAs that will induce phenotypic remodeling have the advantage of being
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in vitro transcribed from cDNA clones so there is no limit to the amount available. However,
the limitation of knowing the exact mRNAs necessary to elicit phenotypic remodeling and
the lack of knowledge of the endogenous mRNA modifications may make this approach
problematic for some applications. However, with these limitations in mind, it is clear that
with the ability to more rapidly and completely (e.g all splice forms of RNAs within a cell)
characterize cellular transcriptomes by NextGen sequencing, it will be advantageous to
develop approaches that better permit selection of defined RNAs (and their specific
functional forms) not simply transcription factors but also other perhaps more subtle
modulators of phenotype, for use in TIPeR-mediated phenotypic conversions.
Future development of the TIPeR process will focus on identifying the subset of mRNAs,
which define functional phenotypic homeostasis as well as mRNAs and miRNAs which
work to maintain an epigenetic barrier to phenotypic conversion. These sets of mRNA work
both as a “cellular phenotypic memory” to maintain and sustain an acceptable range of
phenotypes in differentiated cells and to direct a lineage pathway through the process of
development. When this homeostasis is perturbed, the cell may enter a different phenotypic
state, which if inappropriately controlled may lead to production of a dying cell or
alternatingly permit a cell to enter an oncogenic phase. Instead of introducing an excess
amount of RNA, one can put specified amounts of any single or multiple RNAs in order to
modulate the ratio of mRNAs to generate/maintain a given phenotype. In this manner the
expression profile of a desired cell type can be placed into a host cell with the goal of this
specific expression profile eliciting that phenotype. It is also important to note that as RNA
is the inducer in the TIPeR approach, that the RNA will degrade under normal cellular
conditions thereby removing the inducer thereby overcoming any issues with aberrant
constant overexpression caused by promoter driven DNA constructs. Finally, it is also
possible to repeatedly TIPeR a cell so that the amount of RNA and their ratios can be altered
in a defined manner to insure that high enough levels of RNA are present to induce
phenotype remodeling but also varying the ratios of RNA to more closely resemble
developmental changes that may facilitate chromatin remodeling and phenotype emergence.
Using TIPeR, it is possible to take advantage of the ability to modify homeostasis and
overcome cellular epigenetic barriers. With this approach, the addition of miRNA should
lower the epigenetic barrier and allow the total amount of inductive mRNA to be reduced.
Further, by more selectively adding mRNA specifically involved with the generation of a
given phenotype, the ability to directly phenoconvert with a minimum number of RNA
transfections will be increased.
Finally given the ease with which cell phenotype can be converted by alteration of a cells
expression profile, it is possible and perhaps likely that endogenous cells undergo
phenotypic conversion in response to particular stimuli. Such stimuli may include viral
infection of cells where the introduced virus modulates host cell gene expression to produce
a distinct cell type or perhaps introduction of RNAs into cells from released endosomes
from other cells that then function in the host cell to modify phenotype. While there is scant
but accumulating evidence that this may indeed be the case it is reasonable to investigate the
underlying process of RNA memory stabilization of phenotype as it may prove to be an
effective way of manipulating endogenous cells and therefore provide a novel but important
therapeutic area for drug discovery.
Box 1. Considerations in RNA mediated methodology
RNA advantages
• No vector required –expression through in vivo transcription.
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• Can add specific and known amounts of RNA –no need for promoter driven
regulation.
• No need for the RNA to go to the nucleus (as for vector mediated transfer) can
be directly used in the cell cytoplasm.
• Can be directed to specific subcellular sites where activity can be enhanced.
• RNA is transient so exogenous influence is removed –no long term deleterious
effect of added reagent.
• Can add multiple RNAs in specified ratios –can position anywhere in phenotype
shell.
• Allows the use of RNA populations with edited and spliced forms of RNAs that
may be necessary for conversion.
• Process can be repeated until desired phenotype is reached.
• No integration to the genome, no DNA break or damage, no danger of
malignancy as is the case with factors of DNA.
Potential RNA disadvantages
• RNA may need to be enzymatically capped and poly-adenylated to increase
intracellular translational efficiency.
• RNA addition may need to be repeated multiple times.
• May need to inhibit host transcription transiently to facilitate TIPeR.
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Glossary Box
Totipotency The ability of cell to produce all types of differentiated
cells.
Pluripotency The ability of a stem cell to generate three germ layers,
endoderm, mesoderm and ectoderm.
SNT or SCNT (Somatic Cell
Nuclear Transfer)
A technique to create a cloned embryo by transferring
donor nucleus into enucleated egg cell.
Transdifferentiation/
phenotype conversion
A biological process that transforms already
differentiated cell into another differentiated cell type.
iPS cell (Induced Pluripotent
Stem cell)
iPS cells are artificially-induced pluripotent cells
derived from non-pluripotent cells by introduction of
high levels of exogeneous transcription factors.. The
most commonly used transcription factors are Oct4,
Sox2, Klf4, c-Myc and Nanog.
ES cell (Embryonic Stem cell) ES cells are pluripotent cells derived from the inner
mass of a blastocyst in an early embryo.
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TIPeR (Transcriptome
Induced Phenotype
Remodeling)
A methodology that converts one cellular phenotype to
another cellular phenotype by introducing multiple
RNAs into host cell.
tAstrocyte (transcriptome-
effected Astrocyte)
tAstrocytes are astrocyte-like cells derived nonastrocyte
cells by TIPeR methodology.
tCardiomyocyte
(transcriptome-effected
Cardiomyocyte)
tCardiomyocytes are cardiomyocyte-like cells derived
from noncardiomyocyte cells by TIPeR methodology.
tPS cell (TIPeR Pluripotent
Stem cell)
tPS cells are induced pluripotent stem cells generated
from RNAs encoding or containing pluripotency
inducing factors.
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Figure 1.
A schematic of three different cellular reprogramming methods. Somatic nuclear transplant
transfers a whole nucleus from a cell into an enucleated fertilized oocyte (Top). The
introduction of defined transcription factors dedifferentiates a somatic cell to a pluripotent
stem cell (iPSC) which redifferentiates into a new cell type of interest using specific
differentiation media or other transcription factors (Middle). TIPeR methodology skips
intermediate iPSC generation and directly transdifferentiates a source cell into a target cell
via transfer of the transcriptome (mRNA) (Bottom). For TIPeR, the whole transcriptome is
extracted from source cells and poly-A+ RNAs are isolated. The isolated poly-A+ RNAs are
transfected into recipient cell to induce transdifferentiation.
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Figure 2.
A schematic illustration of TIPeR conversion. The effect of transcriptome transfer is
modulated by the initial cell state. The transcriptomes of individual cells of type A (A1–A4)
are modified through an initial transfection. The transfected cells will either resist phenotype
change (A1), shift status to a transient unstable state and return to the original state (A2) or
escape the stable state (A3, A4). The escaped cells may enter an intermediate state (open
blue circle or A' in the pink cloud) or may shift phenotype to the edge of cell type B and
then spontaneously converted into phenotype (B). A second introduction of transcriptome to
A’ facilitates the transdifferentiation of A' located in intermediate state to cell type B.
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Figure 3.
Transcriptome modulation is regulated by both mRNA and miRNA. (a). The addition of
mRNAs drives transdifferentiation towards a target transcriptome while the addition of
miRNA suppresses the source 480 transcriptome. (b) A single introduction of mRNA may
not be sufficient to reach the required threshold for phenotype transformation (TiPeR
Threshold). A repeated cycle of TIPeR (Upper) would allow the cell to pass the threshold.
Alternately, the introduction of miRNA could lower the epigenetic landscape barrier (Lower
panel), consequently enhancing TiPeR efficiency. The strength of cellular phenotypic
memory can be modulated by the amount of mRNA or miRNA applied as well as the length
of time the mRNA or miRNA is available for the phenotype conversion process.
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